

DAC  
Rfw

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 12 day of July 2006.

By


(Signature of person mailing)

Andrea E. Dorigo

Reg. No. 47,532

(Typed or printed name of person)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: **Herbig et al**APPLICATION NO.: **09/380,825**FILING DATE: **May 4 2004**TITLE: **SOLUBILIZED SERTRALINE  
COMPOSITIONS**

Examiner:

Group Art Unit:

Mail Stop Petition

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

**PETITION FOR REVIVAL OF UNINTENTIONALLY ABANDONED****APPLICATION UNDER 37 C.F.R. §1.137(b)**

Applicants respectfully petition for revival of the above-captioned application. An Official Action was mailed by the USPTO on October 21, 2004. Due to an inadvertent error, the case was transferred from the docket of one attorney to the docket of the undersigned attorney, who was not aware either of the Official Action or of the 6-month deadline (including extension of time) to respond to the Official Action. Accordingly, the application currently went abandoned.

A response to the Official Action is enclosed. Pursuant to 37 CFR 1.137(b), applicants also state the following:

a) the entire delay in either entering national phase in the U.S. or filing a continuation application from the due date January 21, 2005 until the filing of a grantable petition under 37 CFR § 1.137(b) was unintentional;


b) since this utility/plant application was filed on October 21, 2004, no terminal disclaimer is required; and

c) the petition fee is the fee for other than a small entity under 37 CFR § 1.17(m).

The Commissioner is hereby authorized to charge this fee to Deposit Account No. 16-1445.

The Commissioner is also hereby authorized to charge any fees required under 37 C.F.R. §§1.16 and 1.17 or to credit any overpayment to Deposit Account No. 16-1445. Two copies of this paper are enclosed.

Date: July 12, 2006

  
\_\_\_\_\_  
Andrea E. Dorigo  
Attorney for Applicant(s)  
Reg. No. 47,532

Pfizer Inc  
Patent Department  
150 East 42nd Street – 5<sup>th</sup> Floor  
New York, NY 10017-5755  
(212) 733-1898